Literature DB >> 14574011

Double primary cancers of the breast and thyroid in women: molecular analysis and genetic implications.

T Pal1, N Hamel, D Vesprini, K Sanders, M Mitchell, N Quercia, N Ng Cheong, A Murray, W Foulkes, S A Narod.   

Abstract

Multiple primary cancers are characteristic of hereditary cancer syndromes. A familial association between breast and thyroid cancer has been suggested, but a genetic basis for this association has not yet been established. To determine the extent to which double primary cancers of the breast and thyroid are due to common hereditary factors, we conducted a registry- and hospital-based study in Ontario and Quebec. We obtained family histories of 74 women diagnosed with both cancer of the breast and thyroid before 70 years of age. Cancer histories were obtained for the 533 first- degree relatives of these women. The observed cancer rate in the relatives was compared with the expected number, based on age- standardized Canadian cancer incidence rates, and relative risks were estimated. A total of 87 cancers were observed in the relatives, compared to 93.7 expected cancers, giving a relative risk of 0.9 (95% confidence interval (CI): 0.7-1.1). The risk for breast cancer was 1.1 (95% CI: 0.6-1.7) and the risk for thyroid cancer was 0.7 (95% CI: 0-3.8). Blood samples were collected on 53 patients for mutational analysis of the BRCA1, BRCA2, and PTEN genes. One woman was found to be a carrier of a BRCA1 mutation (exon 11 3227delT). Our findings do not support the hypothesis that a significant proportion of double primary cancers of the breast and thyroid are due to hereditary factors.

Entities:  

Mesh:

Year:  2001        PMID: 14574011     DOI: 10.1023/a:1011541424424

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  48 in total

1.  The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Authors:  J P Struewing; P Hartge; S Wacholder; S M Baker; M Berlin; M McAdams; M M Timmerman; L C Brody; M A Tucker
Journal:  N Engl J Med       Date:  1997-05-15       Impact factor: 91.245

2.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

Review 3.  Hereditary breast and ovarian cancer: epidemiology, genetics, screening and predictive testing.

Authors:  W D Foulkes; S A Narod
Journal:  Clin Invest Med       Date:  1995-12       Impact factor: 0.825

4.  Frequency of breast cancer attributable to BRCA1 in a population-based series of American women.

Authors:  B Newman; H Mu; L M Butler; R C Millikan; P G Moorman; M C King
Journal:  JAMA       Date:  1998-03-25       Impact factor: 56.272

5.  Cowden's disease: a cutaneous marker of breast cancer.

Authors:  M H Brownstein; M Wolf; J B Bikowski
Journal:  Cancer       Date:  1978-06       Impact factor: 6.860

6.  Leukemia in Utah and radioactive fallout from the Nevada test site. A case-control study.

Authors:  W Stevens; D C Thomas; J L Lyon; J E Till; R A Kerber; S L Simon; R D Lloyd; N A Elghany; S Preston-Martin
Journal:  JAMA       Date:  1990-08-01       Impact factor: 56.272

7.  Multiple primary malignant neoplasms in breast cancer patients in Israel.

Authors:  J G Schenker; R Levinsky; G Ohel
Journal:  Cancer       Date:  1984-07-01       Impact factor: 6.860

8.  Thyroid cancer and multiple primary malignancies in Israel.

Authors:  M Stein; J Lachter; A Bartal; G Rennert; A Kuten
Journal:  J Surg Oncol       Date:  1991-08       Impact factor: 3.454

9.  Breast cancer and other second neoplasms after childhood Hodgkin's disease.

Authors:  S Bhatia; L L Robison; O Oberlin; M Greenberg; G Bunin; F Fossati-Bellani; A T Meadows
Journal:  N Engl J Med       Date:  1996-03-21       Impact factor: 91.245

10.  Thyroid carcinoma and hyperparathyroidism after radiation therapy for adolescent acne vulgaris.

Authors:  S A De Jong; J G Demeter; H Jarosz; A M Lawrence; E Paloyan
Journal:  Surgery       Date:  1991-10       Impact factor: 3.982

View more
  3 in total

1.  Germline PARP4 mutations in patients with primary thyroid and breast cancers.

Authors:  Yuji Ikeda; Kazuma Kiyotani; Poh Yin Yew; Taigo Kato; Kenji Tamura; Kai Lee Yap; Sarah M Nielsen; Jessica L Mester; Charis Eng; Yusuke Nakamura; Raymon H Grogan
Journal:  Endocr Relat Cancer       Date:  2015-12-23       Impact factor: 5.678

Review 2.  The contribution of inherited factors to the clinicopathological features and behavior of breast cancer.

Authors:  W D Foulkes; J Rosenblatt; P O Chappuis
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-10       Impact factor: 2.673

3.  Investigating the association of rs2910164 with cancer predisposition in an Irish cohort.

Authors:  T P McVeigh; R J Mulligan; U M McVeigh; P W Owens; N Miller; M Bell; F Sebag; C Guerin; D S Quill; J B Weidhaas; M J Kerin; A J Lowery
Journal:  Endocr Connect       Date:  2017-09-12       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.